Cysteine cathepsins, stefins and extracellular matrix degradation during invasion of transformed human breast cell lines

Radiology and Oncology

Volumn 40, Issue 4, 2006, Pages 259-271

  Zajc, Irena ^a   Bervar, Aleš ^a   Lah, Tamara T ^a  

^a NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

Author keywords

Breast neoplasms; Cathepsins; Extracellular matrix; Neoplasms invasiveness; Tumor cells, cultured

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CYSTEINE; STEFIN;

ANTIBODY LABELING; ARTICLE; BREAST CELL; CANCER CELL CULTURE; CELL INVASION; CELL TRANSFORMATION; CONFOCAL MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; ONCOGENE C H RAS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 33846451415     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta 2004; 342: 41-69.
2. Xing R, Addington AK, Mason RW. Quantification of cathepsins B and L in cells. Biochem J 1998; 332: 499-505.
3. Linebauch BE, Sameni M, Day NA, Sloane BF, Keppler D. Exocytosis of active cathepsin B. Eur J Biochem 1999; 264: 100-9.
4. Frosch BA, Berquin I, Emmert.Buck M, Moin K, Sloane BF. Molecular recognition, membrane association and secretion of tumour cathepsin B. APMIS 1999; 107: 28-37.
5. Collette J, Ulku AS, Der CJ, Jones AS, Erickson AH. Enhanced Cathepsin L expression is mediated by different ras effector pathways in fibroblasts and epithelial cells. Int J Cancer 2004; 112: 190-9.
6. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 1992; 282: 273-78.
7. Felbor U, Dreier L, Bryant RAR, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19: 1187-94.
8. Ishidoh K, Kominami E. Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem Biophys Res Commun 1995; 217: 624-31.
9. Kihara M, Kakegawa H, Matano Y, Murata E, Tsuge H, Kido H, et al. Chondroitin sulfate proteoglycan is a potent enhacer in the processing of procathepsin L. Biol Chem 2002; 383: 1925-29.
10. Schmitt M, Janicke F, Graeff F. Tumour-associated proteinases. Fibrinolysis 1992; 6: 3-26.
11. Sameni M, Elliott E, Ziegler G, Fortgens PH, Dennison C, Sloane BF. Cathepsins B and D are localized at the surface of human breast cancer cells. Pathol Oncol Res 1995; 1: 43-53.
12. Cavallo-Medved D, Sloane BF. Cell surface cathepsin B: Understanding its functional significance. Curr Top Dev Biol 2003; 54: 313-31.
13. Lah TT, Kokalj-Kunovar M, Štrukelj B, Pungerčar J, Barlič-Maganja D, Drobnič-Košorok M, et al. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 1992; 50: 36-44.
14. Foekens JA, Kos J, Peters HA, Krašovec M, Look MP, Cimerman N, et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998; 16: 1013-21.
15. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, et al. Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin Cancer Res 1995; 1: 741-6.
16. Lah TT, Čerček M, Blejec A, Kos J, Gorodetsky E, Somers R, et al. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L and other clinical indicators. Clin Cancer Res 2000; 6: 578-84.
17. Calkins CC, Sloane BF. Mammalian cysteine protease inhibitors: Biochemical properties and possible roles in tumour progression. Biol Chem 1995; 376: 71-80.
18. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer. Oncol Rep 1998; 5: 1349-61.
19. Kos J, Werle B, Brunner N. Cysteine proteinases and their inhibitorsin extracellualr fluids: Markers for diagnosis and prognosis in cancer. Int J Biol Markers 2000; 15: 84-9.
20. Kos J, Lah TT. Cystatins in cancer. In: Kopitar Jerala N, Žerovnik E, editors. Human stefins and cystatins, molecular anatomy and physiology of proteins series. New York: NOVA Science Publishers Inc; 2006.
21. Turk D, Gunčar G. Lysosomal cysteine proteases (cathepsins): promising targets. Acta Crystallogr 2003; D 59: 203-13.
22. Bervar A, Zajc I, Sever N, Katunuma N, Sloane BF, Lah TT. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol Chem 2003; 384: 447-55.
23. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line MCF10. Cancer Res 1990; 50: 6075-86.
24. Basolo F, Elliott J, Tait L, Chen XQ, Maloney T, Russo IH, et al. Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinogenesis 1991; 4: 25-35.
25. Dawson PJ, Wolman SR, Tait L, Heppner G, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996; 148: 313-9.
26. Santner SJ, Dawson PJ, Tait L, Soule H, Eliason J, Mohamed AN, et al. Malignant MCF10CA1 cell lines derived from premalignant breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001; 65: 101-10.
27. Bervar A. Localization of cathepsins B and L and their inhibitors, stefins A and B in the invasiveness of breast cancer cell lines. PhD thesis. Ljubljana: Ljubljana University; 2002.
28. Premzl A, Zavašnik-Bergant V, Turk V, Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res 2003; 283: 206-14.
29. Lah TT, Calaf G, Kalman E, Shinde BG, Russo J, Jarosz D, et al. Cathepsins D, B and L in breast carcinoma and transformed human breast epithelial cells (HBEC). Biol Chem 1995; 376: 357-63.
30. Zajc I, Sever N, Bervar A, Lah TT. Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumourigenicity of breast cancer cell lines. Cancer Lett 2002; 187: 185-90.
31. Zajc I, Frangež L, Lah TT. Expression of cathepsin B is related to tumourigenicity of breast cancer cell lines. Radiol Oncol 2003; 37: 233-40.
32. Levičar N, Kos J, Blejec A, Golouh R, Vrhovec I, Frkovič-Grazio S, et al. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Det Prev 2002; 26: 42-9.
33. Sinha AA, Jamuar MP, Wilson MJ, Rozhin J, Sloane BF. Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis. Prostate 2001; 49: 172-84.
34. Calkins CC, Sameni M, Koblinski J, Sloane BF, Moin K. Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy. J Histochem Cytochem 1998; 46: 745-51.
35. Sameni M, Moin K, Sloane BF. Imaging proteolysis by living breast cancer cells. Neoplasia 2000; 2: 496-504.
36. Sameni M, Dosescu J, Moir K, Sloane BF. Functional imaging of proteolysis: stromal and inflammatory cells increase tumour proteolysis. Mol Imaging 2003; 2: 1-17.
37. Podgorski I, Linebaugh BE, Sameni M, Jedeszko C, Bhagat S, Cher ML, et al. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia 2005; 7: 207-23.
38. Premzl A, Turk V, Kos J. Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro. J Cell Biochem 2006; 97: 1230-40.
39. Montaser M, Lalmanach G, Mach L. CA-074, but not its methyl ester CA-074Me is a selective inhibitor of cathepsin B witin living cells. Biol Chem 2002; 383: 1306-8.
40. Kjøller L, Engelholm LH, Høyer-Hansen M, Danø K, Bugge TH, Behrendt N. uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Exp Cell Res 2004; 293: 106-16.
41. Curino AC, Engelholm LH, Yamada SS, Holmbeck K, Lund LR, Molinolo AA, et al. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J Cell Biol 2005; 169: 977-85.
42. Montcourrier P, Mangeat PH, Valembois C, Salazar G, Sahuquet A, Duperray C, et al. Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J Cell Sci 1994; 107: 2381-91.